Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708728 | 0.89 | GRIK1 (0.40) | GSK3BKDM4ETRPV1MEN1KMT2A | |
| SCHEMBL6711748 | 0.89 | GRIK1 (0.41) | GSK3BKDM4ETRPV1MEN1KMT2A | |
| SCHEMBL6707719 | 0.87 | ROCK1 (0.41) | MEN1KMT2ALMNARAB9A | |
| SCHEMBL6707679 | 0.87 | SCN9A (0.33) | — | |
| SCHEMBL6713413 | 0.86 | PKM (0.33) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6709838 | 0.85 | KDM4E (0.38) | GSK3BKDM4ETRPV1MEN1KMT2A | |
| SCHEMBL6710197 | 0.85 | GSK3A (0.37) | GSK3BALDH1A1 | |
| SCHEMBL6711914 | 0.85 | HPGD (0.42) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL6710086 | 0.85 | MET (0.38) | LMNAEGLN1 | |
| SCHEMBL6711649 | 0.84 | GRIK1 (0.33) | GSK3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GSK3B 4467/4885KDM4E 1582/4885TRPV1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.